The PANOVA-3 trial is intended for patients who have recently been diagnosed with locally advanced, pancreatic adenocarcinoma that cannot be treated with a surgery. Pancreatic adenocarcinoma is the most common type of pancreatic cancer. This clinical trial is evaluating the safety and efficacy of the NovoTTF-100L(P) System for use in pancreatic adenocarcinoma, when added to gemcitabine and nab-paclitaxel which are normally given to patients in this condition. This medical device delivers Tumor Treating Fields (TTFields) [About TTFields] to the cancer in the abdominal region, where the tumor is located. Novocure Ltd., the trial sponsor, maintains this website to help patients get basic information about the clinical trial and facilitate their accessibility to medical centers that offer participation in the trial. If you would like to take part in the PANOVA-3 trial, please contact one of the participating centers [PANOVA-3 Centers] as soon as possible. If you have questions concerning your medical condition and recommended treatment, please consult with your treating doctor.